SMARCB1 and neoplasm: For example, BRG1 and SNF5/BAF47 bind to the promoters of the p16INK4a and p21CIP/WAP1 cyclin-dependent kinase (CDK) inhibitors and activate their expression in tumor-derived cell lines [12–16].